GenSight will participate to the 27th Annual Congress ESGCT in Barcelona (Spain), from 22-25 October, 2019

One poster will present GS030, our lead gene therapy product candidate, an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).

GS030 – Optogenetics in Retinitis Pigmentosa (RP)

  • Poster title:  Optogenetics in the clinic: PIONEER, a phase 1/2a, open-label, non-tandomized, doseescalation study to evaluate safety and
    tolerability of GS030 in subjects with retinitis pigmentosa
  • Presenter:  Elise Boulanger-Scemama, Fondation Adolphe de Rothschild, Paris, France
  • Date & Time:  Thursday 24 October
  • Poster Session:  Poster Session II / Eye and ear gene therapy
  • Poster#:  P300